Research & Development

Our projects are specifically dedicated to proposing alternative treatments for patients suffering from renal diseases while also developing reliable biomarkers and tools to facilitate the diagnosis and assess treatment outcomes to improve the overall management of the patient.

New products with a huge commercial potential
for CKD treatment and renal lithiasis.

AVEROA’s pipeline is composed of products targeting renal diseases.

Our lead product, Xoanacyl® (AVA1014), received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on March 27, 2025.

With the LUCIOL project, Averoa is working on a unique treatment (AVA2206) with a new mechanism of action for Renal Lithiasis associated with a companion test (AVA2065).

Chronic Kidney Diseases (CKD)

Renal Lithiases

Product Portfolio

Therapeutic Domain

Product Name

Development phase

Description

Therapeutic Areas

Renal Diseases Chronic Kidney Diseases (CKD)

Xoanacyl® (AVA1014)

Registration

Ferric Citrate as Coordination Complex

  • Iron Deficiencies
  • Renal Insufficiency, Chronic
  • Hyperphosphatemia

AVA1014 has been licensed from AKEBIA and is already registered and marketed in US under the Brand Name Auryxia® and in Japan under the Brand Name Riona®.

Positive Opinion from CHMP on March 27, 2025 

See our press releases issues on April 2, 2025

Renal Lithiasis

Rare renal disease

AVA2206

Late preclinical

Antioxidant

  • Rare renal Lithiasis

AVEROA signed a research collaboration and license agreement with IdiBell, CIBER and University of Barcelona for the development to develop and exploit the product in the field of kidney and/or metabolic diseases

AVA2206 has been granted with an Orphan Drug Designation (ODD) by the European Medicine Agency (EMA) and the US FDA.

Renal Lithiasis

Rare renal disease

AVA2065

Preclinical

Biomarker

AVEROA signed a research collaboration and license agreement with IdiBell, CIBER and University of Barcelona for the development to develop and exploit the product in the field of kidney and/or metabolic diseases